组织因子作为恶性肿瘤静脉血栓栓塞复发预测标志物:CATCH 试验的生物标志物分析
CATCH 试验预设分析纳入 900 例癌症合并急性症状性静脉血栓栓塞(VTE)患者,其中 76 例(8.4%)复发;805 例有组织因子(TF)检测样本,TF 最高四分位组(>64.6 pg/mL)复发风险为较低组的 3.3 倍(95%CI 2.1–5.1,P<.001),竞争风险回归中 TF 与 VTE 复发仍强相关(SHR 3.3,95%CI 1.7–6.4)。
要点
- TF 最高四分位组(>64.6 pg/mL)VTE 复发 38/203 例(19%),较低组 34/602 例(6%),相对风险 3.3(95%CI 2.1–5.1,P<.001)。
- 竞争风险回归中 TF 与 VTE 复发相关(SHR 3.3,95%CI 1.7–6.4)。
- 其他显著变量包括肿块致静脉压迫(SHR 3.1,95%CI 1.4–6.5)和肝胆癌(SHR 5.5,95%CI 2.3–13.6)。
核心结论
- 据作者所知,这是首次报告 TF 作为接受抗凝治疗的癌症患者 VTE 复发潜在生物标志物。
- 作者认为风险适应策略可帮助识别可能受益于更强化抗凝方案的高危患者。
研究设计与样本
- CATCH 为随机、多中心试验,比较亭扎肝素 175 IU/kg 每日一次与剂量调整华法林治疗 6 个月,用于癌症合并急性症状性 VTE 患者。
- 研究人群 900 例,复发 VTE 76 例(8.4%),其中 805 例有样本可供 TF 检测。
- 检测 TF ELISA、可溶性 P-选择素、D-二聚体、FVIII 和 C 反应蛋白;采用 Fisher 精确检验筛查与 VTE 的关联,并进行竞争风险回归分析至 VTE 复发时间,校正多个变量。
主要发现
- TF 均值 72.5 pg/mL、中位数 50.3 pg/mL(范围 15.6–4,798 pg/mL)。
- TF 最高四分位组(>64.6 pg/mL)VTE 复发 38/203 例(19%),较低组 34/602 例(6%),相对风险 3.3(95%CI 2.1–5.1,P<.001)。
- 竞争风险回归中 TF 与 VTE 复发仍强相关(SHR 3.3,95%CI 1.7–6.4)。
- 其他显著变量包括肿块致静脉压迫(SHR 3.1,95%CI 1.4–6.5)和肝胆癌(SHR 5.5,95%CI 2.3–13.6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Circulating tissue factor (TF) has been studied as a biomarker for predicting initial, but not recurrent, venous thromboembolism (VTE) in cancer, a setting in which predictors are incompletely understood. We evaluated the association of TF, clinical risk factors, and other biomarkers measured at the time of initial VTE with recurrent VTE in a prespecified analysis of the CATCH (Comparison of Acute Treatments in Cancer Hemostasis) trial. Methods CATCH was a randomized, multicenter trial that investigated tinzaparin 175 IU/kg once daily or dose-adjusted warfarin for 6 months in patients with cancer and acute, symptomatic VTE. TF ELISA, soluble P-selectin, d-dimer, FVIII, and C-reactive protein were assayed. Fisher's exact test was used to screen for association with VTE; competing risk regression analysis of time to recurrent VTE was conducted, accounting for multiple variables. Results The study population comprised 900 patients (recurrent VTE, n = 76; 8.4%). Of these patients, 805 had samples available for TF assay. Mean and median TF levels were 72.5 pg/mL and 50.3 pg/mL, respectively (range, 15.6 pg/mL to 4,798 pg/mL). Patients in the highest quartile of TF experienced the greatest VTE recurrence (> 64.6 pg/mL; 38 [19%] of 203 patients v 34 [6%] of 602 patients; relative risk, 3.3; 95% CI, 2.1 to 5.1; P < .001). In competing risk regression analysis of time to recurrent VTE, TF remained strongly associated with recurrent VTE (subdistribution hazard ratio [SHR], 3.3; 95% CI, 1.7 to 6.4). Other significant variables included venous compression from mass (SHR, 3.1; 95% CI, 1.4 to 6.5) and hepatobiliary cancer (SHR, 5.5; 95% CI, 2.3 to 13.6). Conclusion This is the first report, to our knowledge, to describe TF as a potential biomarker of recurrent VTE in patients with cancer who are on anticoagulation treatment. A risk-adapted strategy could help identify high-risk patients who may benefit from more intensive anticoagulation approaches.
引用
- Khorana AA, Kamphuisen PW, Meyer G, et al. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. J Clin Oncol. 2016. PMID: 28029329. doi:10.1200/JCO.2016.67.4564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。